肌少症的評估與預後

Assessment and Prognosis of Sarcopenia

周怡君(Yi-Chun Chou) ； 張皓翔(Hao-Hsiang Chang) ； 詹鼎正(Ding-Cheng Chan)

《台灣醫學》 18卷3期 (2014/05) Pp. 303-309

https://doi.org/10.6320/FJM.2014.18(3).05

摘要

肌少症的定義由單純的肌肉量減少，經由許多共識會議，逐漸進展到肌肉量、肌力及生理功能的綜合評估，理想的評估工具需考量準確性、安全性、可近性、成本等，目前以雙能量X射線吸收儀（dual energy x-ray absorptiometry, DXA）或生物電阻抗分析（bioelectrical impedance analysis, BIA）評估肌肉量、以握力評估肌力及以行走速度評估生理功能為主，但切點仍有人種、地區上的不同，定義及切點確立之後，將有助於臨床上有效的篩檢出肌少症的高危險群，做進一步的預防與介入。肌少症與許多不良預後相關，包括失能、罹病率及死亡率增加等，近期的研究逐漸開始探討肌少症與其他老年症候群（例如：認知障礙、憂鬱、及跌倒）的關聯，但目前台灣的研究以橫斷性研究為主，未來仍需更多縱貫性的研究，了解肌少症可能帶來的不良預後。

關鍵字

肌少症 ； 生理功能 ； 肌力 ； 肌肉量 ； 老人

並列摘要

The original definition of sarcopenia was loss of skeletal muscle mass. Through many consensus conferences, the definition gradually evolved to loss of muscle mass plus deficiencies in muscle strength or physical performance. An ideal assessment tools should take accuracy, safety, accessibility, and costs into consideration. Currently, the main assessments include dual energy x-ray absorptiometry (DXA) and/or bioelectrical impedance analysis (BIA) for muscle mass, grip strength for muscle strength and gait speed as an indicator for physical performance. However, there is still geographical difference of the cut-off values for each indicator. It is of paramount importance to establish national or regional criteria of sarcopenia to target high risk groups for prevention and intervention. Sarcopenia is associated with many adverse outcomes, including disability, morbidity and mortality. Recent research has gradually explored the relationship between sarcopenia and other geriatric syndromes (e.g., cognitive impairment, depression, and fall). However, the studies in Taiwan were mainly of cross-sectional design. Future longitudinal studies on the associations of sarcopenia and adverse outcomes are needed.

並列關鍵字

sarcopenia ； physical performance ； muscle strength ； muscle mass ； elderly

參考文獻

1. Rolland Y, Czerwinski S, Abellan Van Kan G, et al: Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives. J Nutr Health Aging 2008;12: 433-50.

2. Baumgartner RN, Koehler KM, Gallagher D, et al: Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 1998;147:755-63.

3. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al: Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010;39:412-23.

4. Muscaritoli M, Anker SD, Argilés J, et al: Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia- anorexia in chronic wasting diseases" and "nutrition in geriatrics". Clin Nutr 2010;29: 154-9.

5. Fielding RA, Vellas B, Evans WJ, et al: Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc 2011;12:249-56.